期刊文献+

T1aN0M0期浸润性肺腺癌术后复发的危险因素分析 被引量:9

Risk factors of recurrence for resected T1aN0M0 invasive lung adenocarcinoma:a clinicopathologic study of 177 patients
原文传递
导出
摘要 目的 探讨完整切除的病理分期为T1aN0M0的肺腺癌术后复发的危险因素.方法 分析177例接受肺叶切除的T1aN0M0浸润性肺腺癌病例,根据国际肺腺癌新病理分型系统(IASLC/ATS/ERS)进行重新分型.分析年龄、性别、吸烟史、淋巴血管浸润(LVI)、新病理分型与无复发生存(RFS)率的关系,统计学分析使用Log-rank检验和Cox回归.结果 总体5年无复发生存率为83.7%.LVI和新病理分型与5年无复发生存率有相关(P<0.05).低危组中的乳头状、鳞屑样、腺泡样为主型的预后显著优于高危组中的混合乳头状、实性和微乳头状为主型.男性患者中高危组的患者更多[校正比值比(OR):2.214,95%可信区间(CI):1.050 -4.668,P<0.05],且LVI有相对更多的趋势(校正OR:2.091,95% CI:0.938 -4.662,P>0.05).结论 IASLC/ATS/ERS新病理分型中的实性和微乳头状为主型是T1aN0M0期肺腺癌术后复发的唯一危险因素,提示这类肿瘤的生物学行为更具侵袭性. Objective To identify risk factors of recurrence for completely resected pathologic T1aN0M0 lung adenocarcinomas.Methods We reviewed the records of 177 T1aN0M0 invasive adenocarcinoma patients,and re-classified achieved surgical specimens according to the new International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) lung adenocarcinoma classification.Impact on recurrence-free survival (RFS) of age,gender,smoking history,lymphovascular invasion (LVI) and new classification was analyzed by Log-rank test and Cox regression.Results The 5-year recurrence-free rate was 83.7%.The LVI and new adenocarcinoma classification were significantly associated with 5-year RFS (P < 0.05,respectively).This high-grade group is associated with significantly more male gender [adjusted OR:2.214,95% confidence interval (CI):1.050-4.668,P <0.05],and borderline significantly the presence of LVI (adjusted OR:2.091,95% CI:0.938-4.662,P > 0.05).Conclusion Our results showed that the solid-and micropapillary predominant subtype of IASLC/ATS/ERS classification remains the only risk factor for post-operative recurrence of T1aN0M0 adenocarcinomas,suggesting that they can be indicators of aggressive tumor behaviors.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2014年第8期1639-1641,共3页 Chinese Journal of Experimental Surgery
关键词 肺腺癌 复发 lung adenocarcinoma Recurrence
  • 相关文献

参考文献3

二级参考文献17

  • 1高尚志.我国心胸外科实验研究目前的热点和问题[J].中华实验外科杂志,2006,23(9):1031-1032. 被引量:3
  • 2Chenyang S, Hui Z. Molecular cloning, identification and analysis of lung squamous cell carcinoma-related genes. Lung Cancer, 2002, 67:235-241.
  • 3Tokunaga K, Nakamura Y. Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancer. Cancer Res,1987,47:5616.
  • 4Zhong H, Simons J W. Direct comparison of GAPDH, beta-actin, cyclophilin and 28s rRNA as internal standards for quantifying RNA levels under hypoxia. Biochem Biophys Res Commun, 1999, 259: 523-526.
  • 5Deindl E, Boengler K. Differential expression of GAPDH and beta3-actin in growing collateral arteries. Mol Cell Biochem, 2002, 236: 139-146.
  • 6Tsuji N, Kamagata C. Selection of an internal control gene for quantitation of mRNA in colonic tissues. Anticancer Res, 2002, 22:4173-4178.
  • 7Fuster G, Vicente R. One-step reverse transcription polymerase chain reaction for semiquantitative analysis of mRNA expression. Methods Find Exp Clin Pharmacol, 2002, 24: 253-259.
  • 8Sambrook J, Russell DW. Molecular Cloning: A Laboratory Manual,3rd ed. Cold Spring Harbor Laboratory Press, 2001,8: 46-54.
  • 9Hirsch FR, Witta S. Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer. Curt Opin Oncol,2005,17 : 118-122.
  • 10Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst ,2005,97:643-655.

共引文献740

同被引文献73

  • 1罗扬,冯奉仪,要洁,张湘茹,王绿化,张德超.231例非小细胞肺癌术后生存和预后分析[J].中国肿瘤临床,2005,32(2):92-94. 被引量:11
  • 2张敏鸣,周华,邹煜.肺癌肿瘤血管生成CT及MR灌注成像研究[J].放射学实践,2005,20(4):286-290. 被引量:20
  • 3张德超,毛友生,黄国俊.中国肺癌外科治疗概况与进展[J].中国肺癌杂志,2005,8(6):557-562. 被引量:28
  • 4Han YH,Moon HJ,You BR,et al.The attenuation of MG132,a proteasome inhibitor,induced A549 lung cancer cell death by p38 inhibitor in ROS-independent manner[J].Oncol Res,2010,18 (7):315-322.
  • 5Strauss GM,Herndon JE 2 nd,Maddaus MA,et al.Adjuvant paclitaxel plus carboplatin compared with observation in stage Ⅰ B nonsmall-cell lung cancer:CALGB 9633 with the cancer and leukemia group B,radiation therapy oncology group,and north central cancer treatment group study groups[J].J Clin Oncol,2008,26 (31):5043-5051.
  • 6Arriagada R,Dunant A,Pignon JP,et al.Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatinbased chemotherapy in resected lung cancer[J].J Clin Oncol,2010,28 (1):35-42.
  • 7Lzbicki JR,Passlick B,Pantel K,et al.Effectiveness of redical systematic mediastinal lymphadenectomy in patients with respectable non-small cell lung cancer:results of a prospective randomized trial[J].Ann Surg,1998,227(1):138-144.
  • 8Bonner JA,Garces YI,Sawyer TE,et al.Frequency of noncontiguous lymph node involvement in patients with respectable nonsmall cell lung carcinoma[J].Cancer,1999,86(7):1159-1164.
  • 9Ludwig MS,Goodman M,Miller DL,et al.Postoperative survival and the number of lymph nodes sampled during resection of nodenegative non-small cell lung cancer[J].Chest,2005,128 (3):1545-1550.
  • 10Riquet M,Assouad J,Bagan P,et al.Skip mediastinal lymph node metastasis and lung cancer:a particular N2 subgroup with a better prognosis[J].Ann Thorae Surg,2005,79(1):225-233.

引证文献9

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部